Quintiles to invest US$ 14 mn to set up Lab Testing Solution in China
Quintiles has inked a pact with the Shanghai Clinical Research Centre (SCRC) and has committed an investment to the tune of US$ 14 million to open lab test facility in Feng Lin Science Park which is designed to achieve Leed Gold accreditation.
It is expected to accommodate over 450 employees in the next five years. Quintiles new 4,000-square-meter base at Shanghai will serve China and nearby Asian countries.
“These investments and agreements demonstrate our commitment to this District and to China. We recognise the needs of our customers in China. By collaborating with SCRC in labs we can help local and international biopharma companies develop new and better medicines to serve China’s enormous unmet medical needs,” said Ling Zhen, general manager, Quintiles operations in China.
SCRC’s Central Laboratory’s experienced staff and modern technology will be further enhanced through Quintiles’ investments. We are delighted to work closely with Quintiles to further biopharma innovation and improve human health, said Rongxing Gan, president of SCRC.
The Quintiles-SCRC collaboration follows last year’s launch of Kun Tuo, Quintiles’ local contract research organization, built to help local and global biopharma companies achieve successful registration of medicines in China. Quintiles commenced operations in China in 1997, and has existing offices in Beijing, Dalian, Hong Kong and Shanghai, with employees and capabilities to serve all major population centres and study sites across China.
Chenggang Zhu, Vice Mayor of the Shanghai Xuhui District People’s Government and executives from the SCRC, Quintiles’ strategic partner in the China-based lab initiative, joined Quintiles’ executives at the ceremony.
“With its burgeoning economy and growing healthcare needs for its 1.3 billion citizens, China offers good opportunities. By broadening our investment and infrastructure, Quintiles is ready to partner with our biopharma customers as they look to realize China’s potential,” said Dennis Gillings, executive chairman, Quintiles.